RxDoctor Payments DataLook up a doctor →

Steven Stone, PA

Medical · Kalamazoo, MINPI 1932480720

Payments from drug & device makers

$199,895in general payments, 2019–2025

Across 483 payments — averaging $413.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$77K
  • GSK$40K
  • Amgen$36K
  • Apellis Pharmaceuticals, Inc.$22K
  • Novartis$13K
  • E.r. Squibb & Sons, L.L.C.$4K
  • plus $8K from 40 others

What the payments were for

  • Consulting fees$23,84012%
  • Speaking & faculty fees$136,35668%
  • Travel & lodging$28,33714%
  • Food & beverage$9,9585%
  • Education$1,4051%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$199,895 in reported general payments places this provider in the 95th percentile of 755 medical providers in Michigan.

See all medical providers in Michigan

Medicare billing

Part B allowed, 2024
$16,047
Medicare patients
191
Services billed
262

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide43$723,305
Lenalidomide48$654,965
PomalystPomalidomide26$578,406
JakafiRuxolitinib Phosphate18$305,934
ImbruvicaIbrutinib12$186,716
VenclextaVenetoclax24$180,994
EliquisApixaban61$52,791
XareltoRivaroxaban21$14,761
Posaconazole13$9,765
Enoxaparin Sodium28$9,618
Acyclovir79$1,519
Hydroxyurea36$769
Dexamethasone17$493
Potassium Chloride18$258
Gabapentin11$204

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$580$723,30543 claims
E.r. Squibb & Sons, L.L.C.Pomalyst$3,595$578,40626 claims
Incyte CorporationJakafi$172$305,93418 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$187$186,71612 claims
AbbVieVenclexta$109$180,99424 claims
PfizerEliquis$423$52,79161 claims
Johnson & JohnsonXarelto$137$14,76121 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 755 medical providers in Michigan.

Other medical in Kalamazoo

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →